HCV infection selectively impairs type i but not type III IFN signaling

American Journal of Pathology

Volumn 184, Issue 1, 2014, Pages 214-229

  Chandra, Partha K ^a   Bao, Lili ^a   Song, Kyoungsub ^a   Aboulnasr, Fatma M ^a   Baker, Darren P ^b   Shores, Nathan ^a   Wimley, William C ^a   Liu, Shuanghu ^c   Hagedorn, Curt H ^c   Fuchs, Serge Y ^d   Wu, Tong ^a   Balart, Luis A ^a   Dash, Srikanta ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BIOGEN   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA INTERFERON RECEPTOR; ALPHA1 INTERFERON; ALPHA1 INTERFERON RECEPTOR; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; GAMMA INTERFERON; JANUS KINASE; RIBAVIRIN; SMALL INTERFERING RNA; STAT PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; AUTOPHAGY; CONTROLLED STUDY; DRUG UPTAKE; ENDOPLASMIC RETICULUM STRESS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; LONG TERM CARE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION; VIRAL CLEARANCE; VIRUS REPLICATION;

ANTIVIRAL AGENTS; AUTOPHAGY; BLOTTING, WESTERN; CELL LINE, TUMOR; ENDOPLASMIC RETICULUM STRESS; HEPACIVIRUS; HEPATITIS C; HEPATOCYTES; HUMANS; INTERFERON TYPE I; INTERFERON-GAMMA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; VIRUS REPLICATION;

EID: 84890410562     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2013.10.005     Document Type: Article

References (42)

1. M.J. Alter Epidemiology of hepatitis C virus infection World J Gastroenterol 13 2007 2436 2441
2. C.W. Shepard, L. Finelli, and M.J. Alter Global epidemiology of hepatitis C virus infection Lancet Infect Dis 5 2005 558 567
3. A.A. Butt, and F. Kanwal Boceprevir and telaprevir in the management of hepatitis C virus-infected patients Clin Infect Dis 54 2012 96 104
4. G.J. Dore, G.V. Matthews, and J. Rockstroh Future of hepatitis C therapy: development of direct-acting antivirals Curr Opin HIV AIDS 6 2011 508 513
5. P. Halfon, and S.J. Locarnini Hepatitis C virus resistance to protease inhibitors Hepatology 55 2011 192 206
6. J.M. Pawlotsky Treatment failure and resistant with direct-acting antiviral drugs against hepatitis C virus Hepatology 53 2011 1742 1751
7. A. Aronsohn, and N. Reau Long-term outcomes after treatment with interferon and ribavirin in HCV patients J Clin Gastroenterol 43 2009 661 671
8. H. Yoshida, Y. Arakawa, M. Sata, S. Nishiguchi, M. Yano, S. Fujiyama, G. Yamada, O. Yokosuka, Y. Shiratori, and M. Omata Interferon therapy prolonged life expectancy among chronic hepatitis C patients Gastroenterology 123 2002 483 491
9. S. Datta, S. Hazari, P.K. Chandra, M. Samara, B. Poat, F. Gunduz, W.C. Wimley, H. Hauser, M. Koster, C. Lamaze, L.A. Balart, R.F. Garry, and S. Dash Mechanisms of HCV's resistance to IFN-alpha in cell culture involve expression of functional IFN-alpha receptor 1 Virol J 8 2011 351
10. S. Hazari, P.K. Chandra, B. Poat, S. Datta, R.F. Garry, T.P. Foster, G. Kousoulas, T. Wakita, and S. Dash Impaired antiviral activity of interferon alpha against hepatitis C virus 2a in Huh-7 cells with a defective Jak-Stat pathway Virol J 7 2010 36
11. S. Hazari, L. Taylor, S. Haque, R.F. Garry, S. Florman, R. Luftig, F. Regenstein, and S. Dash Reduced expression of Jak-1 and Tyk-2 proteins leads to interferon resistance in hepatitis C virus replicon Virol J 4 2007 89
12. S.M. Lemon Induction and evasion of innate antiviral responses by hepatitis C virus J Biol Chem 285 2010 22741 22747
13. K.D. Ibarra, and J.K. Pfeiffer Reduced ribavirin antiviral efficacy via nucleoside transporter-mediated drug resistance J Virol 83 2009 4538 4547
14. A. Rauch, Z. Kutalik, P. Descombes, T. Cai, J. Di Iulio, T. Mueller, M. Bochud, M. Battegay, E. Bernasconi, J. Borovicka, S. Colombo, A. Cerny, J.F. Dufour, H. Furrer, H.F. Günthard, M. Heim, B. Hirschel, R. Malinverni, D. Moradpour, B. Müllhaupt, A. Witteck, J.S. Beckmann, T. Berg, S. Bergmann, F. Negro, A. Telenti, P.Y. Bochud Swiss Hepatitis C Cohort Study Swiss HIV Cohort Study Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study Gastroeneterology 138 2010 1338 1345
15. V. Suppiah, M. Moldovan, G. Ahlenstiel, T. Berg, M. Weltman, M.L. Abate, M. Bassendine, U. Spengler, G.J. Dore, E. Powell, S. Riordan, D. Sheridan, A. Smedile, V. Fragomeli, T. Müller, M. Bahlo, G.J. Stewart, D.R. Booth, and J. George IL-28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy Nat Genet 41 2009 1100 1104
16. S. Liu, C.A. Nelson, L. Xiao, L. Lu, P.P. Seth, D.R. Davis, and C.H. Hagedorn Measuring antiviral activity of benzimidazole molecules that alters IRES RNA structure with an infectious hepatitis C virus chimera expressing Renilla luciferase Antiviral Res 89 2011 54 63
17. D. Sir, W.L. Chen, J. Choi, T. Wakita, T.S. Yen, and J.H. Ou Induction of incomplete autophagic response by hepatitis C virus via the unfolded protein response Hepatology 48 2008 1054 1061
18. P.K. Chandra, A.K. Kundu, S. Hazari, S. Chandra, L. Bao, T. Ooms, G.F. Morris, T. Wu, T. Mandal, and S. Dash Inhibition of hepatitis C virus replication by intracellular delivery of multiple siRNAs by nanosomes Mol Ther 20 2012 1724 1736
19. P.K. Chandra, S. Hazari, B. Poat, F. Gunduz, R. Prabhu, G. Liu, R. Burioni, M. Clementi, R.F. Garry, and S. Dash Intracytoplasmic stable expression of IgG1 antibody targeting NS3 helicase inhibits replication of highly efficient hepatitis C virus 2a clone Virol J 7 2010 118
20. M. Wang, W. Tan, J. Zhou, J. Leow, M. Go, H.S. Lee, and P.J. Casey A small molecule inhibitor of isoprenylcysteine carboxymethyltransferase induces autophagic cell death in PC3 prostate cancer cells J Biol Chem 283 2008 18678 18684
21. C.M. Henriques, J. Rino, R.J. Nibbs, G.J. Graham, and J.T. Barata IL-7 induces rapid clathrin-mediated internalization and JAK3-dependent degradation of IL-7Ralpha in T cells Blood 115 2010 3269 3277
22. C.W. Dunnett A multiple comparison procedure for comparing several treatments with a control J Am Stat Assoc 50 1955 1096 1121
23. H. Abdi Bonferroni test. Encyclopedia of Measurement and Statistics N.J. Salkind, 2007 Sage Thousand Oaks, CA 103 107
24. O. Bauhofer, A. Ruggieri, B. Schmid, P. Schirmacher, and R. Bartenschlager Persistence of HCV in quiescent hepatic cells under conditions of an interferon-induced antiviral response Gastroenterology 143 2012 429 438.e8
25. E. Merquiol, D. Uzi, T. Mueller, D. Goldenberg, Y. Nahmias, R.J. Xavier, B. Tirosh, and O. Shibolet HCV causes chronic endoplasmic reticulum stress leading to adaptation and interference with the unfolded protein response PLoS One 6 2011 e24660
26. M. Ogata, S. Hino, A. Saito, K. Morikawa, S. Kondo, S. Kanemoto, T. Murakami, M. Taniguchi, I. Tanii, K. Yoshinaga, S. Shiosaka, J.A. Hammarback, F. Urano, and K. Imaizumi Autophagy is activated for cell survival after endoplasmic reticulum stress Mol Cell Biol 26 2006 9220 9230
27. B. Poat, S. Hazari, P.K. Chandra, F. Gunduz, X. Alvarez, L.A. Balart, R.F. Garry, and S. Dash Intracellular expression of IRF-9 Stat fusion protein overcome defective Jak-Stat signaling and inhibits HCV RNA replication Virol J 7 2010 265
28. B. Poat, S. Hazari, P.K. Chandra, F. Gunduz, L.A. Balart, X. Alvarez, and S. Dash SH2 modified STAT1 induces HLA-1 expression and improves IFN-γ signaling in IFN-α resistant HCV replicon cells PLoS One 5 2010 e13117
29. W. Kong, K. Engel, and J. Wang Mammalian nucleoside transporters Curr Drug Metab 5 2004 63 84
30. M.W. Fried, M.L. Shiffman, K.R. Reddy, C. Smith, G. Marinos, F.L. Gonçales Jr., D. Häussinger, M. Diago, G. Carosi, D. Dhumeaux, A. Craxi, A. Lin, J. Hoffman, and J. Yu Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection N Engl J Med 347 2002 975 982
31. M.P. Manns, J.G. McHutchison, S.C. Gordon, V.K. Rustgi, M. Shiffman, R. Reindollar, Z.D. Goodman, K. Koury, M. Ling, and J.K. Albrecht Peginterferon alfa-2a plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial Lancet 358 2001 958 965
32. K.R. Reddy, M.L. Shiffman, M. Rodriguez-Torres, H. Cheinquer, D. Abdurakhmanov, I. Bakulin, V. Morozov, G.F. Silva, N. Geyvandova, C. Stanciu, M. Rabbia, M. McKenna, J.A. Thommes, S.A. Harrison PROGRESS Study Investigators Induction pegylated interferon alfa-2a and high dose ribavirin do not increase SVR in healthy patients with genotype 1a and high viral loads Gastroenterology 139 2010 1972 1983
33. J. Liu, W.C. HuangFu, K.G. Kumar, J. Qian, J.P. Casey, R.B. Hamanaka, C. Grigoriadou, R. Aldabe, J.A. Diehl, and S.Y. Fuchs Virus-induced unfolded protein response attenuates anti-viral defenses via phosphorylation-dependent degradation of type I interferon receptor Cell Host Microbe 5 2009 72 83
34. P.Y. Ke, and S.S. Chen Activation of the unfolded protein response and autophagy after hepatitis C virus infection suppresses innate antiviral immunity in vitro J Clin Invest 121 2011 37 56
35. S. Shrivastava, A. Raychoudhury, R. Steele, R. Ray, and R.B. Ray Knockdown of autophagy enhances the innate immune response in hepatitis C virus-infected hepatocytes Hepatology 53 2011 406 414
36. S. Shrivastava, J. Bhanja Chowdhury, R. Steele, R. Ray, and R.B. Ray Hepatitis C virus up regulates beclin1 for induction of autophagy and activates mTOR signaling J Virol 86 2012 8705 8712
37. T. Asselah, E. Estrabaud, I. Bieche, M. Lapalus, S. De Muynck, M. Vidaud, D. Saadoun, V. Soumelis, and P. Marcellin Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin Liver Int 30 2010 1259 1269
38. P.E. Rautou, D. Cazals-Hatem, G. Feldmann, A. Mansouri, A. Grodet, S. Barge, M. Martinot-Peignoux, A. Duces, I. Bièche, D. Lebrec, P. Bedossa, V. Paradis, P. Marcellin, D. Valla, T. Asselah, and R. Moreau Changes in autophagic response in patients with chronic hepatitis C virus infection Am J Pathol 178 2011 2708 2715
39. J. Qian, H. Zheng, W.C. Huangfu, J. Liu, C.J. Carbone, N.A. Leu, D.P. Baker, and S.Y. Fuchs Pathogen recognition receptor signaling accelerates phosphorylation-dependent degradation of IFNAR1 PLoS Pathog 7 2011 e1002065
40. B. Langhans, B. Kupfer, I. Braunschweiger, S. Arndt, W. Schulte, H.D. Nischalke, J. Nattermann, J. Oldenburg, T. Sauerbruch, and U. Spengler Interferon-lambda serum levels in hepatitis C J Hepatol 54 2011 859 965
41. X. Shi, Y. Pan, M. Wang, D. Wang, W. Li, T. Jiang, P. Zhang, X. Chi, Y. Jiang, Y. Gao, J. Zhong, B. Sun, D. Xu, J. Jiang, and J. Niu IL28B genetic variation is associated with spontaneous clearance of hepatitis C virus, treatment response, serum IL-28B levels in Chinase population PLoS One 7 2012 e37054
42. T. Marcello, A. Grakoui, G. Barba-Spaeth, E.S. Machlin, S.V. Kotenko, M.R. MacDonald, and C.M. Rice Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics Gastroeneterology 131 2006 1887 1898